Early Warning System

EIB-20200938

ROVI PHARMA TECHNOLOGY RDI II

Early Warning System

ROVI PHARMA TECHNOLOGY RDI II

EIB-20200938

Quick Facts

Countries	Spain
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2022-07-18
Borrower	LABORATORIOS FARMACEUTICOS ROVI SA
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	$ 54.52 million
Project Cost (USD)	$ 124.31 million

Project Description

According to the Bank’s website, the project concerns the Promoter's research, development and innovation (RDI) activities in various drug delivery technologies, including preclinical development and clinical studies.

ROVI's pharmacological investigations involved in the project strengthen ROVI's innovativeness and help the company to maintain its competitive edge and expand its international footprint.

Investment Description

- European Investment Bank (EIB)

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	LABORATORIOS FARMACEUTICOS ROVI SA	Client	-

Contact Information

ACCESS TO INFORMATION

No contact information provided at the time of disclosure.

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces

Bank Documents

- Environmental and Social Data Sheet (ESDS) - ROVI PHARMA TECHNOLOGY RDI II

Media

- Spain: The EIB and ROVI spur innovation in the pharmaceutical sector

Other Related Projects

- EIB-20210118 MIDCAP PROGRAMME LOAN SPAIN AND PORTUGAL 3